Viromed Medical AG, a medical technology company specializing in cold plasma technology, has announced the signing of new distribution partnerships for its ViroCAP® product. The agreements cover Spain, Portugal, Greece, the Balkan region, Romania, and Saudi Arabia, significantly broadening the company's international footprint. Each partnership is with a separate company and pertains to an individual market, with minimum purchase quantities agreed upon. Based on these contracts, Viromed anticipates additional sales of at least 3,000 devices per year.
ViroCAP® is a mobile medical device designed for the treatment of skin conditions using cold atmospheric plasma. It is intended for use by hospitals, private practice physicians, and surgically active medical specialists. The device represents a pioneering application of cold plasma technology in medicine, offering a non-invasive approach to wound healing and dermatological treatments.
Uwe Perbandt, Chief Executive Officer of Viromed Medical AG, commented on the development: "With these new distribution partners, we are opening up several attractive markets in Southern and South-Eastern Europe as well as in the Middle East. The strong interest shown by our distribution partners underlines the high demand for our cold plasma technology. The new distribution partnerships are another important step in the implementation of our dynamic growth phase. Partnerships for additional countries are in preparation and are expected to be signed within the next four to six weeks."
This expansion follows a series of strategic moves by Viromed to build a robust international distribution network. The company already has numerous distribution and marketing partnerships in place, including an exclusive distribution agreement with South Korea's UMECO covering ten Asian countries, and a partnership with TriPart TITAN GmbH & Co. KG for the Turkish market. These alliances are crucial for Viromed as it seeks to penetrate diverse healthcare markets and capitalize on the growing adoption of advanced medical technologies.
The significance of these new partnerships lies in Viromed's ability to leverage local expertise to navigate regulatory landscapes and establish a strong market presence. By securing minimum purchase commitments, Viromed ensures a steady revenue stream, which is vital for its growth phase. The company's focus on cold plasma technology positions it at the forefront of a niche but expanding field, with potential applications beyond dermatology, including dentistry and veterinary medicine.
Viromed Medical AG, listed on the stock exchange since October 2022, operates through its wholly owned subsidiary Viromed Medical GmbH. The company has built a broad customer base in the DACH region (Germany, Austria, Switzerland) and beyond, and aims to further advance the use of cold plasma technology in medicine. With the addition of these six new markets, Viromed is poised to strengthen its competitive edge and drive innovation in medical treatments.
The announcement comes at a time when the global medical device market is experiencing rapid growth, driven by technological advancements and an increasing demand for minimally invasive treatments. Viromed's strategic expansion into Southern and Eastern Europe, as well as the Middle East, aligns with these trends and reflects the company's commitment to bringing its innovative products to a wider patient population.
For more information about Viromed Medical AG and its products, visit their official website at https://www.viromed-medical-ag.de.
